Mallinckrodt plc (MNK) Receives Price Target

Mallinckrodt plc (MNK) : The highest level Mallinckrodt plc (MNK) is projected to reach is $115 for the short term and the lowest estimate is at $82. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $94.83 and the possibility the share price can swing is $10.55.

Mallinckrodt plc (MNK) : 13 analysts are covering Mallinckrodt plc (MNK) and their average rating on the stock is 1.04, which is read as a Strong Buy. 12 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Mallinckrodt plc (MNK) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels.


Also, Brokerage firm Barclays maintains its rating on Mallinckrodt plc (NYSE:MNK). In a research note issued to the investors, the brokerage major maintains price-target of $88 per share.The shares have been rated Overweight. The rating by the firm was issued on August 25, 2016.

Mallinckrodt plc (NYSE:MNK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $74.50 and $74.03 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $75.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $75.59, notching a gain of 1.41% for the day. The total traded volume was 1,274,090 . The stock had closed at $74.54 on the previous day.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *